You are not going to hear a lot of revenue guidance about Lympro. Want to know why Dave? If you are listening, the business model is buy an asset, build value of the asset, and have an exit strategy. Lympro will be sold. AMBS will uplist, they will spin out the diagnostic division, pay a dividend or something similar, then sell the diagnostic division. So, they are not going to comment long term on Lympro revenue because another company will own it and market it. So, stop already.